HOPKINTON, Mass., Aug. 28, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that a scientific abstract that includes additional data from the first cohort of the ongoing ACHIEVE clinical trial of SB 9200 will be presented at the 2017 International HBV Meeting on the Molecular Biology of Hepatitis B Viruses, to be held September 3-7, 2017 in Washington D.C. The abstract will be presented orally as part of a Satellite Symposium: “New HBV Antiviral and Immune Modulatory Therapies in Late Pre-Clinical/Clinical Development.”
The Satellite Symposium, organized by Dr. Anna S. Lok, University of Michigan, and Dr. Marc Ghany, NIH, is scheduled for Thursday, September 7th from 8:15 am – 12:30 pm EDT at the Marriott Waldman Hotel in Washington D.C. The Satellite Symposium will provide an overview of gaps in knowledge of current and future HBV treatment, as well as a discussion on endpoints and designs of clinical trials aimed at HBV cure.
Nezam Afdhal M.D., D.Sc., Chief Medical Officer of Spring Bank Pharmaceuticals, will present the company’s abstract at Session II of the Satellite Symposium on Thursday, September 7th from 10:45 am – 11:00 am EDT.
Abstract #112526: Phase IIa ACHIEVE Clinical Trial of SB 9200: Results from the Tenofovir Switch Segment of the 25mg Cohort, MF Yuen et al.
The ongoing ACHIEVE trial is a placebo-controlled phase 2 study of SB 9200 in HBV treatment-naïve patients. Each cohort receives 12 weeks of monotherapy with SB 9200 at doses of 25mg, 50mg, 100mg, 200mg or placebo and is then subsequently switched to tenofovir1 300mg (TDF) daily for 12 weeks (week 12 – 24). Spring Bank previously reported top-line results showing that the low dose (25mg) of SB 9200 alone showed a favorable safety profile and antiviral activity against HBV DNA and HBsAg. Administration of SB 9200 resulted in a statistically significant reduction in HBV DNA at week 12 (unpaired t-test 2.85, p=0.01) compared to placebo, with a mean reduction of 0.6 log10 (range 0 to 1.87 log10) in the SB 9200 treatment group. Complete data on the full 25mg cohort after the switch to TDF will be presented at the Satellite Symposium.
Following the company’s presentation of the abstract, a copy of presentation materials can be accessed by visiting the Investors & Media section of the company’s website at www.springbankpharm.com and selecting “Presentations.”
For more information on the International HBV Meeting refer to http://www.hbvmeeting.org/
About Spring Bank
Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. SMNH compounds are small segments of nucleic acids that the company designs to selectively target and modulate the activity of specific proteins implicated in various disease states. The company is developing its most advanced SMNH product candidate, SB 9200, for the treatment of viral diseases, including hepatitis B virus (HBV) and other SMNH product candidates, including SB 11285, the Company’s lead immunotherapeutic agent for the treatment of selected cancers through the activation of the STimulator of INterferon Genes, or STING, pathway.
Forward-Looking Statements
Statements in this press release about Spring Bank’s future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether Spring Bank’s cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; whether results obtained in preclinical studies and clinical trials will be indicative of results obtained in future clinical trials; whether Spring Bank’s product candidates will advance through the clinical trial process on a timely basis, or at all; whether the results of such trials will warrant submission for approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether Spring Bank’s product candidates will receive approval from regulatory agencies on a timely basis or at all; whether, if product candidates obtain approval, they will be successfully distributed and marketed; and other factors discussed in the “Risk Factors” section of Spring Bank’s Annual Report on Form 10-K for the year ended December 31, 2016, which was filed with the Securities and Exchange Commission (SEC) on February 14, 2017, Spring Bank’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2017, which was filed with the SEC on July 31, 2017, and in other filings Spring Bank makes with the SEC from time to time.
In addition, the forward-looking statements included in this press release represent Spring Bank’s views as of the date hereof. Spring Bank anticipates that subsequent events and developments will cause Spring Bank’s views to change. However, while Spring Bank may elect to update these forward-looking statements at some point in the future, Spring Bank specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Spring Bank’s views as of any date subsequent to the date hereof.
1. Gilead Sciences’ Viread®
Contacts For investor inquires: Spring Bank Pharmaceuticals, Inc. Jonathan Freve Chief Financial Officer (508) 473-5993 jfreve@springbankpharm.com
